M

Merck

Makes medicines, vaccines and animal treatments

Engineering COE Lead

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
No salary listed
Expert
Bachelor's
Upper Hutt, New Zealand
In Person
Engineering ManagementEngineering Leadership

About the job

Requirements
  • Strong communication, organizational and interpersonal skills and the ability to operate in a matrix environment.
  • Continuous improvement, strategic management and change management skills to define and translate high-level strategies into operational and interpersonal expectations.
  • Strong understanding of maintenance and reliability, validation, facilities management and capital project delivery, ideally within a Good Manufacturing Practice-regulated environment.
  • Significant leadership experience within a Good Manufacturing Practice-regulated biological, pharmaceutical, biotechnology or related manufacturing environment.
  • Business and financial acumen, with advanced knowledge and application of engineering finance and economics.
  • A bachelor's degree or equivalent qualification with academic working and thinking level in Engineering, Science, Biotechnology or a related discipline.
  • Knowledge and application of Engineering Standards, estimation and planning, manufacturing scale-up, pharmaceutical quality assurance, professional engineering, resource forecasting, site supervision, team collaboration, technical mentoring and technical problem-solving.
Responsibilities
  • Contribute to the strategic direction and long-term success of the Upper Hutt site as a member of the Site Leadership Team.
  • Develop and adapt site strategy, identify and prioritize key site projects and key performance indicators, and track strategic performance through senior leadership reviews.
  • Sponsor site strategic workstreams and translate strategies into site and Engineering Centre of Excellence priorities, targets and projects.
  • Strengthen Site Leadership Team effectiveness through collaboration, communication and an open feedback culture.
  • Foster an inclusive culture in which colleagues feel respected, valued and able to contribute, including through Diversity, Equity and Inclusion initiatives.
  • Lead and develop a team of three managers and three specialists by providing guidance, training and performance evaluations.
  • Coach and continuously improve daily and weekly cross-functional performance management forums to drive prioritization, alignment and accountability.
  • Conduct routine one-to-one meetings and on-floor coaching to strengthen management systems, develop team capability and actively manage succession planning.
  • Embed continuous improvement by empowering teams to solve problems at the appropriate level using lean manufacturing methodologies.
  • Promote a strong safety and compliance culture through active leadership presence on the manufacturing floor.
  • Maintain integrated management systems that support the value stream through reliable assets, compliant validation and effective project delivery, while making risks and improvement opportunities visible and driving timely resolution.
  • Maintain operational review meetings and shop-floor engagement processes to ensure performance meets budget and forecast expectations and legal, safety, quality and financial compliance requirements are met.
  • Own relevant site-wide Safety and Quality Systems and mentor Subsystem Owners to establish more effective and efficient standards.
  • Be accountable for people, safety, quality, delivery and cost performance across the Engineering Centre of Excellence.
  • Shape the site's long-range asset, infrastructure and capital investment strategy.
  • Govern the capital portfolio to ensure compliant, on-time and on-budget project delivery.
  • Ensure maintenance and reliability capabilities support safe, compliant and reliable supply.
  • Ensure risk-based validation strategies are embedded across routine operations and capital projects.
  • Lead Facilities and Shared Services to deliver safe, reliable and cost-effective support to the value stream.
  • Ensure hazards and environmental aspects in the areas of responsibility are identified, documented, assessed and controlled in accordance with Environmental Health and Safety procedures.
  • Develop Environmental Health and Safety objectives, targets and performance indicators, establish improvement projects and review progress.
  • Ensure employees receive appropriate Environmental Health and Safety training, instruction and supervision to work safely and responsibly.
  • Compile Environmental Health and Safety reports as required by management, regulatory authorities and others.
  • Identify and record Environmental Health and Safety monitoring requirements and implement appropriate monitoring.
  • Ensure scheduled audits and inspections for which the role is responsible are conducted and that necessary corrective actions are developed and completed.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 28th, 2026
Merck's oncology wins lift outlook, but 110x P/E clouds its $141.82 share price

Merck (MRK) is drawing investor attention after oncology trials showed meaningful survival benefits for KEYTRUDA, sacituzumab tirumotecan, and a melanoma vaccine developed with Moderna. The shares closed at $141.82, down 4.37% over seven days and 4.68% over 30 days. They are still up 33.23% this year and 67.74% over one year in total shareholder return. A popular narrative puts fair value at $159.76, making the stock 11% undervalued. Merck plans more than 20 new growth drivers, with management pointing to over $70 billion in mid-2030s revenue potential to offset the KEYTRUDA loss of exclusivity. Valuation remains contested. Merck trades at 110.3 times earnings, against a fair ratio of 50.2, a US pharmaceuticals average of 15.7, and peers at 33.9. Its profit margin is 4.8%.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Becker's Hospital Review
Oct 22nd, 2026
Vaccine reduces risk of melanoma recurrence, death by 42%: What to know.

Vaccine reduces risk of melanoma recurrence, death by 42%: What to know. By: Elizabeth Gregerson Receiving a personalized mRNA-based cancer vaccine alongside immunotherapy lowered the risk of recurrence or death by 42% versus immunotherapy alone in a phase 3 clinical trial of patients with surgically resected stage 2B to 4 melanoma. The vaccine, called intismeran autogene and jointly developed by Merck and Moderna, was tested in combination with Merck's immunotherapy Keytruda after surgery as part of the phase 3 INTerpath-001 trial, according to an Oct. 22 news release from the companies. The trial enrolled 1,137 patients, about two-thirds of whom were randomly assigned to receive the vaccine. The vaccine is given in nine doses and is personalized to include up to 34 neoantigens, or proteins specific to each patient's tumor, according to The New York Times. The trial results were leaked online Oct. 22, The Wall Street Journal reported, two days before Merck and Moderna were expected to present the data at the European Society for Medical Oncology conference in Madrid. The leak prompted Merck, Moderna and ESMO to release the full data early. Here are six notes on the trial results: * In addition to lowering the risk of recurrence or death by 42%, intismeran plus Keytruda lowered the risk of distant metastasis or death by 38% compared with Keytruda alone. * Outcomes in the vaccine group were similar to those for Keytruda alone during the first six months while patients completed the vaccine regimen. After six months, a sensitivity analysis showed a 58% lower risk of recurrence or death and a 50% lower risk of distant metastasis or death versus Keytruda alone. * Results were generally consistent across patient subgroups, and no new safety signals emerged. * Robert Vonderheide, MD, president-elect of the American Association for Cancer Research, told the Times the results are on par with "our biggest breakthroughs." However, neither this trial nor an earlier phase 2 trial has yet shown whether the vaccine improves overall survival, the Times reported. Overall survival is considered the gold standard for determining whether a cancer treatment works and can be a requirement for regulatory approval. * Merck plans to apply for regulatory approval as quickly as possible, Marjorie Green, MD, head of oncology clinical development, told the Times. * Personalized cancer vaccines have also shown promise in small studies in pancreatic, kidney and brain cancers, but not all trials have succeeded. BioNTech ended a phase 2 colorectal cancer trial of its personalized vaccine in August after a recommendation from an independent data safety monitoring board. Read more about the cancer vaccine landscape here. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker's is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit We think you might like

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.